Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.25 -0.59 (-5.44%) Market Cap: 1.20 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 7.65 GF Score: 29/100

Q3 2023 Arcutis Biotherapeutics Inc Earnings Call Transcript

Nov 03, 2023 / 12:30PM GMT
Release Date Price: $2.44 (+9.91%)
Operator

Good day and welcome to the Arcutis Biotherapeutics Third-Quarter 2023 earnings conference call. (Operator Instructions)

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Eric McIntyre, Head of Investor Relations. Please go ahead.

Eric McIntyre;Frank Watanabe
Arcutis Biotherapeutics, Inc. - IR;Arcutis

Thank you, Abigail, good morning everyone, and thank you for joining us this morning to discuss our Q3 2023 financial results. Slides for today are available on the Investors section of our website. On the call this morning we have Frank Watanabe, President, and CEO; Todd Edwards, our Chief Commercial Officer; Patrick Burnett Chief Medical Officer, and John Smither, our Chief Financial Officer.

I'd remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties and our actual results may differ. With that, let me hand the call over to Frank.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot